PA

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phan GQ et al. - SLNB provides important prognostic and staging data with minimal morbidity and can be used to identify regional node-negative patients who would not benefit from a complete nodal dissection. In the authors opinion, SLNB should be performed on most patients (with acceptable surgical and anesthesia risk) who have melanomas with a Breslow depth >= 0.76 mm.

Exclusive Author Commentary
Jonathan S. Zager and Giao Phan, 06/30/09

This article adds to the growing body of literature that supports the use of sentinel node biopsy for melanomas. The SLNB is a staging technique that allows for identification of patients who will (or will not) need more surgery and adjuvant therapy. It has been proven to be the single most independant prognostic factor in terms of overall survival in melanoma patients (Gershenwald JCO 2001). Ongoing trials such as the Multicenter Selective Lymphadenectomy Trial II will hopefully determine those patients with positive sentinel nodes who are at risk for further nodal metastases based on primary tumor properties and SLN burden of disease. It is our opinion that this staging method is safe with limited morbidity and adds important prognostic information for clinicians in treating patients with melanoma and should be used for all aptients who are good surgical candidates with melanomas greater than 0.75 mm thick.

   

Related Articles

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09    Relevance Score: 97%

Slow-growing melanoma: a dermoscopy follow-up study
British Journal of Dermatology, 10/05/09    Relevance Score: 93%

Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09    Relevance Score: 91%

ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
Journal of Investigative Dermatology, 11/03/09    Relevance Score: 91%

KIT as a Therapeutic Target in Melanoma
Journal of Investigative Dermatology, 10/23/09    Relevance Score: 90%

Today in Hematology/Oncology...keeping you current

Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis
Anti-Cancer Drugs, 12/09/09

Developments in factor Xa inhibitors for the treatment of thromboembolic disorders
Medicinal Research Reviews, 12/09/09

Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy
Medicinal Research Reviews, 12/09/09